Journal ArticleDOI
"The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual".
Margo Michaels,Elisa S. Weiss,John A. Guidry,Natasha Blakeney,Liz Swords,Brian K. Gibbs,Samantha Yeun,Bruce Rytkonen,Robert M. Goodman,S. Lisbeth Jarama,Amanda Greene,Shilpa Patel +11 more
Reads0
Chats0
TLDR
A pilot program sought to change knowledge, attitudes, and role behaviors among community leaders, primary care providers, and clinical researchers about CCTs, to increase patient awareness of and participation in C CTs.Abstract:
Only 3% of cancer patients participate in cancer clinical trials (CCTs). A number of barriers to participation, particularly for minority groups, can be addressed through community-focused education and advocacy efforts. Working with community partnerships, a pilot program sought to change knowledge, attitudes, and role behaviors among community leaders, primary care providers (PCPs), and clinical researchers about CCTs, to increase patient awareness of and participation in CCTs. A mixed method evaluation utilized quantitative analysis of surveys administered to participants during the program period (2006-2008) and qualitative data from interviews with key participants. Programmatic efforts were effective in increasing knowledge and training community leaders and PCPs to disseminate messages about clinical trials, and ultimately increasing patient inquiries about local trials. Training improved cultural competency skills among clinical researchers to recruit and retain CCT participants. Partnerships fostered new processes and structures to facilitate CCT participation in their communities. Clinical trials education and advocacy efforts through community partnerships have an important role in enhancing clinical trial access and in increasing clinical trial participation. Oncologists' involvement in and leadership of such partnerships are critical to promoting CCT accrual, particularly for minority groups.read more
Citations
More filters
Journal ArticleDOI
Strategies addressing barriers to clinical trial enrollment of underrepresented populations: A systematic review
Caren Heller,Joyce E. Balls-Berry,Jill Dumbauld Nery,Patricia J. Erwin,Dawn Littleton,Mimi Kim,Winston Patrick Kuo +6 more
TL;DR: Multiple and flexible strategies targeting providers and participants at provider sites and within communities might be needed to enroll underrepresented populations into clinical trials.
Journal ArticleDOI
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: Summary and recommendations
Andrea Denicoff,Worta McCaskill-Stevens,Stephen S. Grubbs,Suanna S. Bruinooge,Robert L. Comis,Peggy Devine,David M. Dilts,Michelle E. Duff,Jean G. Ford,Steven Joffe,Lidia Schapira,Kevin P. Weinfurt,Margo Michaels,Derek Raghavan,Ellen S. Richmond,Robin T. Zon,Terrance L. Albrecht,Michael A. Bookman,Afshin Dowlati,Rebecca A. Enos,Mona N. Fouad,Marjorie J. Good,William J. Hicks,Patrick J. Loehrer,Alan P. Lyss,Steven N. Wolff,Debra Wujcik,Neal J. Meropol +27 more
TL;DR: A combination of approaches addressing both the multifactorial nature of accrual challenges and the characteristics of the target population may be needed to improveAccrual to cancer clinical trials.
Journal ArticleDOI
The impact of socioeconomic status on access to cancer clinical trials
TL;DR: This mini-review explores the evidence regarding socioeconomics and access to cancer trials, highlighting the underrepresentation of deprived patients, and exploring reasons for this disparity.
Journal ArticleDOI
Clinical trial awareness: Changes over time and sociodemographic disparities:
TL;DR: Overall clinical trial awareness in the US population has increased between 2008 and 2012, although a large subset of the population still lacks general awareness of clinical trials.
Journal ArticleDOI
Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies.
Joseph M. Unger,Dawn L. Hershman,Raymond U. Osarogiagbon,Anirudh Gothwal,Seerat Anand,Arvind Dasari,Michael J. Overman,Jonathan M. Loree,Kanwal Pratap Singh Raghav +8 more
TL;DR: The poor representation of Black patients in pharmaceutical company–sponsored trials supporting new drug applications could result in the use of new drugs with little data about efficacy or side effects in this key population.
References
More filters
Book
Diffusion of Innovations
TL;DR: A history of diffusion research can be found in this paper, where the authors present a glossary of developments in the field of Diffusion research and discuss the consequences of these developments.
Journal ArticleDOI
Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities
TL;DR: Although the total number of trial participants increased during the study period, the representation of racial and ethnic minorities decreased and were less likely to enroll in cooperative group cancer trials than were whites, men, and younger patients, respectively.
Journal ArticleDOI
Distrust, Race, and Research
TL;DR: Race remained strongly associated with a higher distrust score and even after controlling for markers of social class, African Americans were less trusting than white Americans.
Journal ArticleDOI
Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review.
Jean G. Ford,Mollie W. Howerton,Gabriel Y. Lai,Tiffany L. Gary,Shari Bolen,M. Chris Gibbons,Jon C. Tilburt,Charles Baffi,Teerath Peter Tanpitukpongse,Renee F Wilson,Neil R. Powe,Eric B Bass +11 more
TL;DR: The results indicated that underrepresented populations face numerous barriers to participation in cancer‐related trials, and the available evidence had limitations in quality regarding representativeness, justification of study methods, the reliability and validity of data‐collection methods, potential for bias, and data analysis.